Report Highlights

Beard Care in the United States: Market Overview

The United States beard care market covers beard oils, balms, washes, conditioners and growth serums sold through mass retail, e-commerce and barbershops. Estimated market value reached USD 1.12 billion in 2024, with growth driven primarily by private brands rather than public programs. Federal policy sets the outer boundary: the Federal Food, Drug, and Cosmetic Act, as amended by MoCRA, governs safety, labeling and facility obligations, while the FDA administers compliance.

Market structure is set by private players. Procter & Gamble, through Gillette, and Unilever, through Dollar Shave Club, compete alongside Edgewell Personal Care and independent brands such as Beardbrand and Honest Amish. Government has played no direct role through subsidy, procurement or price control, so the private sector has led product development and channel strategy. Subscription models and barbershop retail have shaped distribution, with regulation acting as a compliance filter rather than a growth driver.

Policy-Driven Growth in US Beard Care

The Modernization of Cosmetics Regulation Act of 2022 (MoCRA), enacted within the Consolidated Appropriations Act, 2023, is the principal demand-side driver. It requires facility registration, product listing and safety substantiation, pushing brands to document formulations and invest in verification. That compliance spend drives reformulation toward documented ingredients, which supports premium-priced products that carry verifiable safety claims. The mechanism is indirect: compliance costs fall hardest on micro-brands, which shifts shelf share toward firms able to absorb fixed costs.

Minnesota's Amara's Law (Minnesota Statutes §116.943) bans intentionally added PFAS in cosmetics from 1 January 2025, and Maine's parallel regime extends restrictions to cosmetics later in the decade. Brands reformulate waterproof and long-wear formulas to PFAS-free bases, creating a PFAS-free differentiator in beard balms and oils. Separately, SBA 7(a) loans of up to USD 5 million lower capital barriers for independent brands entering the category. Lending decisions depend on documented MoCRA compliance, linking capital access to regulatory readiness.

Regulatory Barriers and Compliance Costs

Hair-growth claims carry the heaviest regulatory cost. The FDA's Center for Drug Evaluation and Research regulates topical minoxidil as an OTC drug under 21 CFR Part 310, so growth serums must follow the monograph, carry Drug Facts labeling under 21 CFR 201.66, and meet drug good manufacturing practice. Reformulation to monograph concentrations and label redesign typically adds several months to launch timelines, and brands implying follicle stimulation without compliance face FDA warning letters.

California's Proposition 65, the Safe Drinking Water and Toxic Enforcement Act of 1986, requires clear and reasonable warnings for chemicals on the state's list, administered by the Office of Environmental Health Hazard Assessment. Private plaintiffs enforce it through 60-day notice letters, and lead and certain phthalates, common in personal care formulations, trigger these notices. Separately, Section 5 of the FTC Act requires competent and reliable scientific evidence behind claims such as "clinically proven" growth or "natural" formulation, raising substantiation costs that fall hardest on independent brands.

Policy-Created Opportunities in the United States

Policy creates a clear opening for PFAS-free and documentation-led beard products. Brands that reformulate to meet Minnesota's ban and Maine's parallel rules can market PFAS-free status across the national shelf, not only in restricted states, because a single national formula is cheaper than state-specific SKUs. Documented safety files under MoCRA also create a premium tier for brands able to publish verified ingredient data. Retailers reviewing supplier compliance will favor these brands in planogram reviews.

Made in USA labeling offers a second opportunity. The FTC's Made in USA Labeling Rule, codified at 16 CFR Part 323 and effective 2021, permits "Made in USA" claims only when final assembly and substantially all significant processing occur domestically. Domestic contract manufacturers holding MoCRA-compliant facility registrations supply brands seeking this claim. Finally, SBA 7(a) loans of up to USD 5 million finance contract-manufacturing capacity, giving independent brands a financing route for domestic production lines.

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act of 1938, as amended by the Modernization of Cosmetics Regulation Act of 2022, administered by the U.S. Food and Drug Administration. MoCRA requires facility registration and annual product listing, safety substantiation, and reporting of serious adverse events within 15 business days, and grants FDA mandatory recall authority. The FTC polices advertising under Section 5 of the FTC Act, while Proposition 65 and state PFAS statutes add layers of state-level obligation.

Compliance will tighten further. FDA's cosmetic good manufacturing practice rule, proposed in September 2023, awaits finalization, and its proposed asbestos testing rule for talc-containing cosmetics was issued in December 2024. Against peers, the EU Cosmetics Regulation (EC) No 1223/2009 restricts over 1,300 substances and requires pre-market safety reports, and Canada requires pre-market notification, while U.S. law relies on post-market enforcement. Minnesota's PFAS prohibition took effect in 2025 and is the most consequential state rule.

Long-Term Policy Outlook for US Beard Care

By 2032 the FDA is expected to finalize the cosmetic good manufacturing practice rule, which would convert MoCRA's risk-based framework into enforceable plant-level standards for beard products made in contract facilities. That shift will raise minimum quality costs for private-label producers and accelerate consolidation toward Procter & Gamble, Unilever and Edgewell, which already run compliance systems at scale. Compliance-driven consolidation will reduce the number of active private-label suppliers across the category.

State-level action will extend beyond PFAS. Additional states are expected to adopt Minnesota-style chemical restrictions, and Proposition 65 notices will continue to shape warning labels on fragrance and oil-based products. Growth through 2032 will favor brands that treat cosmetic compliance as a product-design input rather than a post-launch checklist. The forecast assumes USD 1.92 billion market value by 2032 at a 7.0% CAGR, with federal preemption debates determining whether this state patchwork persists.